Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | SVP, Chief Technology Officer | October 29, 2024 | October 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date October 29, 2024 · Filed October 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,138.049 |
Ending reported balance
After 2024-10-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-10-29 · Exercise / conversion · Acquired 458.024 · Balance 3,318.282 Row 2 · 2024-10-29 · Tax withholding · Disposed 180.233 · Balance 3,138.049 |
| Rst. Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2024-10-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-10-29 · Exercise / conversion · Disposed 458.024 · Balance 0 F1: These units were payable in cash or the company's common stock upon the lapse of restrictions on the transaction date shown. F2: Release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: These units were payable in cash or the company's common stock upon the lapse of restrictions on the transaction date shown.
F2: Release of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 29, 2024 Filed Oct 31, 2024 15:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionRst. Stock Unit · Derivative | 458.024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026135 · form4.xml · derivative · entry 3 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 458.024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These units were payable in cash or the company's common stock upon the lapse of restrictions on the transaction date shown. F2 · kind: Release of restricted stock units. F1 · derivative.exercise_date: These units were payable in cash or the company's common stock upon the lapse of restrictions on the transaction date shown. F1 · derivative.expiration_date: These units were payable in cash or the company's common stock upon the lapse of restrictions on the transaction date shown. Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 15:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 180.233 | $318.41 | $57,387.99 |
DisclosureSEC source: 0001127602-24-026135 · form4.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,138.049 Read SEC document |
| October 29, 2024 Filed Oct 31, 2024 15:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 458.024 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026135 · form4.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,318.282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:46 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,800 | $330.78 | $595,404.00 |
DisclosureSEC source: 0001127602-24-018568 · form4.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,860.258 F1 · price: The price reported in column 4 is a weighted average price. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 16:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,012 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001127602-24-007020 · form4.xml · derivative · entry 3 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Stock Options (Right to Buy) · 7,012 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 16:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 7,012 | $365.00 | $2,559,380.00 |
DisclosureSEC source: 0001127602-24-007020 · form4.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660.258 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 16:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 7,012 | $173.22 | $1,214,618.64 |
DisclosureSEC source: 0001127602-24-007020 · form4.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,672.258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 23:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 2,968 | $0.00 Strike: $350.18 | $0.00 |
DisclosureSEC source: 0001127602-24-006389 · form4.xml · derivative · entry 2 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,968 Underlying: Stock Options (Right to Buy) · 2,968 shares Expires 2034-02-20 F2 · derivative.exercise_date: This grant vests in four equal installments beginning on February 20, 2025. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 23:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 646 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006389 · form4.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,660.258 F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:31 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 8,160 | $102.51 Strike: $102.51 | $836,481.60 |
DisclosureSEC source: 0001562180-23-006276 · primarydocument.xml · derivative · entry 4 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,160 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:31 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 6 | $397.69 | $2,386.14 |
DisclosureSEC source: 0001562180-23-006276 · primarydocument.xml · nonDerivative · entry 3 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,209.2997 Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:31 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 8,154 | $397.18 | $3,238,586.15 |
DisclosureSEC source: 0001562180-23-006276 · primarydocument.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,215.2997 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $396.53 to $397.285, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:31 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 8,160 | $102.51 | $836,481.60 |
DisclosureSEC source: 0001562180-23-006276 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,369.2997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,020 | $0.00 Strike: $86.24 | $0.00 |
DisclosureSEC source: 0001562180-23-003795 · primarydocument.xml · derivative · entry 4 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,020 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/26/2019. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 649 | $366.14 | $237,623.89 |
DisclosureSEC source: 0001562180-23-003795 · primarydocument.xml · nonDerivative · entry 3 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,209.2997 F2 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $366.0350 to $366.18, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 7,371 | $365.55 | $2,694,492.64 |
DisclosureSEC source: 0001562180-23-003795 · primarydocument.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,858.2997 F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.91, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| May 01, 2023 Filed May 2, 2023 18:04 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 8,020 | $86.24 | $691,644.80 |
DisclosureSEC source: 0001562180-23-003795 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,229.2997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2023 Filed Mar 22, 2023 20:41 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,500 | $322.57 | $483,850.05 |
DisclosureSEC source: 0001562180-23-003040 · primarydocument.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,209.2997 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $322.50 to $323.00, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 22, 2023 20:41 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 234 | $318.28 | $74,477.52 |
DisclosureSEC source: 0001562180-23-003040 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,709.2997 F1 · kind: Vesting of Bonus & Incentive Grant Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 3,216 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001794 · primarydocument.xml · derivative · entry 2 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,216 Underlying: Stock Options (Right to Buy) · 3,216 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,274 | $306.68 | $697,390.32 |
DisclosureSEC source: 0001562180-23-001794 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,475.2997 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 16:25 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 5,374 | $343.93 | $1,848,306.15 |
DisclosureSEC source: 0001562180-22-005843 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,201.2997 F1 · price: The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $343.69 to $344.10, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:52 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 3,108 | $0.00 Strike: $369.13 | $0.00 |
DisclosureSEC source: 0001562180-22-001879 · primarydocument.xml · derivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,108 Underlying: Stock Options (Right to Buy) · 3,108 shares Expires 2032-02-22 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 20:27 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,498 | $369.13 | $922,086.74 |
DisclosureSEC source: 0001562180-22-001857 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,575.2997 F1 · shares: 2019 PSUs (PP18) award vesting net of taxes withheld Read SEC document |
| May 10, 2021 Filed May 10, 2021 20:49 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 2,171 | $335.00 | $727,285.00 |
DisclosureSEC source: 0001562180-21-003372 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,077.2997 Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 21:49 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 677 | $280.65 | $190,000.05 |
DisclosureSEC source: 0001562180-21-001672 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,248.2997 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:43 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 4,364 | $0.00 Strike: $274.29 | $0.00 |
DisclosureSEC source: 0001562180-21-001590 · primarydocument.xml · derivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,364 Underlying: Common Stock · 4,364 shares Expires 2031-02-23 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/23/2022. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:33 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 2,577 | $272.65 | $702,619.05 |
DisclosureSEC source: 0001562180-21-001571 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,925.2997 F1 · shares: 2018 PSUs (PP17) award vesting net of taxes withheld Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 22:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 1,956 | $275.23 Strike: $275.23 | $538,349.88 |
DisclosureSEC source: 0001562180-20-006502 · primarydocument.xml · derivative · entry 2 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956 Underlying: Common Stock · 1,956 shares Expires 2030-10-29 F2 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 10/29/2021. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 22:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 454 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006502 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,348.2997 F1 · shares: This award fully vests on 10/29/2024. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $86.24 | $0.00 |
DisclosureSEC source: 0001562180-20-003520 · primarydocument.xml · derivative · entry 6 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 Underlying: Common Stock · 1,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/26/2019. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,000 | $204.50 | $204,500.00 |
DisclosureSEC source: 0001562180-20-003520 · primarydocument.xml · nonDerivative · entry 4 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,894.2997 Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,000 | $86.24 | $86,240.00 |
DisclosureSEC source: 0001562180-20-003520 · primarydocument.xml · nonDerivative · entry 3 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,894.2997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 18:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $86.24 | $0.00 |
DisclosureSEC source: 0001562180-20-003520 · primarydocument.xml · derivative · entry 5 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,020 Underlying: Common Stock · 1,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/26/2019. Read SEC document |
| May 08, 2020 Filed May 12, 2020 18:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 1,000 | $200.00 | $200,000.00 |
DisclosureSEC source: 0001562180-20-003520 · primarydocument.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,894.2997 Read SEC document |
| May 08, 2020 Filed May 12, 2020 18:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,000 | $86.24 | $86,240.00 |
DisclosureSEC source: 0001562180-20-003520 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,894.2997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 16:10 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 500 | $0.00 Strike: $86.24 | $0.00 |
DisclosureSEC source: 0001562180-20-003214 · primarydocument.xml · derivative · entry 3 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,020 Underlying: Common Stock · 500 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 16:10 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 500 | $200.66 | $100,328.10 |
DisclosureSEC source: 0001562180-20-003214 · primarydocument.xml · nonDerivative · entry 2 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,541 F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $200.445 to $201.0509, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 16:10 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 500 | $86.24 | $43,120.00 |
DisclosureSEC source: 0001562180-20-003214 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 13, 2020 13:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 370 | $156.49 | $57,901.30 |
DisclosureSEC source: 0001562180-20-002455 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,541 F1 · shares: Portion of bonus paid in stock Read SEC document |
| February 26, 2020 Filed Mar 2, 2020 13:58 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 471 | $158.30 | $74,559.30 |
DisclosureSEC source: 0001562180-20-001829 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,171 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:08 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 7,012 | $0.00 Strike: $173.22 | $0.00 |
DisclosureSEC source: 0001562180-20-001428 · primarydocument.xml · derivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,012 Underlying: Common Stock · 7,012 shares Expires 2030-02-18 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 20:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 477 | $106.14 | $50,628.78 |
DisclosureSEC source: 0001562180-19-001636 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,642 F1 · shares: Bonus & Incentive share grant Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 20:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 473 | $103.77 | $49,083.21 |
DisclosureSEC source: 0001562180-19-001481 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,165 F1 · kind: Shares withheld solely for the purpose of satisfying tax liability due upon vesting of restricted stock award. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 23:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 8,160 | $102.51 Strike: $102.51 | $836,481.60 |
DisclosureSEC source: 0001562180-19-001180 · primarydocument.xml · derivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 Underlying: Common Stock · 8,160 shares Expires 2029-02-19 F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 10,520 | $86.24 Strike: $86.24 | $907,244.80 |
DisclosureSEC source: 0001562180-18-001326 · primarydocument.xml · derivative · entry 2 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,520 Underlying: Common Stock · 10,520 shares Expires 2028-02-26 F2 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/26/2019. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:37 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 4,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001326 · primarydocument.xml · nonDerivative · entry 1 Abraham Silji · CIK 0001733001 · Chief Digital & Trans Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,638 F1 · shares: This award vests over 3 years starting on the 1st anniversary date of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.